Research Papers:

Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis

Yuhua Ma, Jie Yang, Ruozheng Wang _, Zegao Zhang, Xiaoli Qi, Chunhua Liu and Miaomiao Ma

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:31509-31520. https://doi.org/10.18632/oncotarget.15663

Metrics: PDF 1334 views  |   HTML 2091 views  |   ?  


Yuhua Ma1,2, Jie Yang1, Ruozheng Wang2, Zegao Zhang1, Xiaoli Qi1, Chunhua Liu1 and Miaomiao Ma1

1Radiotherapy Second Department, People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang, China

2The Department of Radiation Oncology, Tumor Hospital Affiliated To Xinjiang Medical University, Urumqi, Xinjiang, China

Correspondence to:

Ruozheng Wang, email: [email protected]

Keywords: Aurora kinase A, cervical squamous cell carcinoma, radiation, Uyghur, cell cycle

Received: August 23, 2016    Accepted: January 27, 2017    Published: February 24, 2017


Background: Definitive radiation therapy (RT) (with or without cisplatin-based chemotherapy) is one of the most effective treatments for cervical squamous cell carcinoma (CSCC), but efficacy is limited due to resistance. In the present study, we investigated the relationship between the expression of Aurora kinase A (Aurora-A, AURKA)and response to RT in patients with CSCC.

Methods: The expression of Aurora-A in biopsy specimens of untreated primary tumors in 129 Uyghur patients with CSCC was investigated immunohistochemically. Primary treatment in these patients was definitive radical RT, which consisted of pelvic RT plus brachytherapy (total point A dose:70–85 Gy) (with or without cisplatin-based chemotherapy). The prognostic value of tumoral Aurora-A expression and patients’ clinical outcomes were evaluated.

Results: Aurora-A expression was significantly associated with lymph node metastasis (P<0.001), large tumor size (P<0.001), low hemoglobin (Hb) level (P=0.011) and recurrence (P<0.001), but not other clinicopathological factors. Definitive RT was unfavorable in patients with high Aurora-A expression (P < 0.001). In 129 enrolled patients, lymph node metastasis, large tumor size, low Hb level, and AURKA overexpression were prognostic factors for both recurrent free survival (RFS) and overall survival (OS) in univariate analysis. However, only high AURKA expression was an adverse independent risk factor for both RFS (hazard ratio, 3.953; 95% CI, 1.473-10.638; P = 0.006) and OS (hazard ratio 9.091; 95%CI 2.597-32.258; P<0.001) in multivariate analyses.

Conclusions: Aurora-A may serve as a predictive biomarker of radiation response and a therapeutic target to reverse radiation therapy resistance.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15663